Tyvaso DPI: Drug-device characteristics and patient clinical considerations

By sjmartinez • November 16, 2023

McEvoy C, Argula R, Sahay S, Shapiro S, Eagan C, Hickey AJ, Smutney C, Dillon C, Winkler T, Davis B, Broderick M, Burger C. Tyvaso DPI: Drug-device characteristics and patient clinical considerations. Pulm Pharmacol Ther. 2023 Nov 13:102266. doi: 10.1016/j.pupt.2023.102266. Epub ahead of print. PMID: 37967762.

Tags: Cardiology/Epi, Inhaled, prostacyclin, Publications, pulmonary arterial hypertension, pulmonary drug delivery, Pulmonary hypertension with interstitial lung disease, Treprostinil, Veterans Administration

A case report of verapamil toxicity leading to haemodynamic compromise in obstructive hypertrophic cardiomyopathy

Gau JW, Rader F, Mody B, Lee AY. A case report of verapamil toxicity leading to haemodynamic compromise in obstructive hypertrophic cardiomyopathy. Eur Heart J[...]

Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF

Shoji S, Kaltenbach L, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Thibodeau JT, Chapman BM, Oliver-McNeil SM, Felker[...]

A Review of Photon-Counting Computed Tomography (PCCT) in the Diagnosis of Cardiovascular Diseases

Sharma A, Cerdas MG, Reza-Soltani S, Rustagi V, Guntipalli M, Rojas Torres DS, Bhandari M, Kandel S, Teja Rayaprolu D, Hussain M. A Review of[...]